Cougar Biotechnology, Inc. is a Los Angeles-based company with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, which is currently being tested in a Phase III clinical trial in prostate cancer and a Phase I/II trial in breast cancer; CB3304, which is currently in a Phase I trial in multiple myeloma; and CB1089, which has been clinically tested in a number of solid tumor types.
On July 10, 2009, Cougar was acquired by Johnson & Johnson, as noted in the press release listed above.
This site is published by Cougar Biotechnology, Inc., which is solely responsible for its contents. This site is governed solely by applicable Federal and State laws and governmental regulations in the United States. It is intended for visitors from the United States. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy.
|
